Trends in overall survival and costs of multiple myeloma, 2000–2014

Little real-world evidence is available to describe the recent trends in treatment costs and outcomes for patients with multiple myeloma (MM). Using the Truven Health MarketScan Research Databases linked with social security administration death records, this study found that the percentage of MM pa...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia 2017-09, Vol.31 (9), p.1915-1921
Main Authors: Fonseca, R, Abouzaid, S, Bonafede, M, Cai, Q, Parikh, K, Cosler, L, Richardson, P
Format: Article
Language:English
Subjects:
692/4028/67/1990/804
692/4028/67/2324
692/699/67
692/700
692/700/1750
692/700/3934
Cancer Research
Care and treatment
Costs
Costs and Cost Analysis - trends
Critical Care Medicine
Delivery of Health Care - economics
Delivery of Health Care - trends
Dexamethasone
Diagnosis
Dosage and administration
Doxorubicin
Drug Costs - trends
Health care
Health risk assessment
Hematology
Humans
Intensive
Internal Medicine
Medicine
Medicine & Public Health
Multiple myeloma
Multiple Myeloma - economics
Multiple Myeloma - mortality
Oncology
Original
original-article
Patient outcomes
Patients
Social security
Stem cell transplantation
Survival
Survival Rate
Therapy
Treatment Outcome
Trends
United States
Vincristine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Little real-world evidence is available to describe the recent trends in treatment costs and outcomes for patients with multiple myeloma (MM). Using the Truven Health MarketScan Research Databases linked with social security administration death records, this study found that the percentage of MM patients using novel therapy continuously increased from 8.7% in 2000 to 61.3% in 2014. Compared with MM patients diagnosed in earlier years, those diagnosed after 2010 had higher rates of novel therapy use and better survival outcomes; patients diagnosed in 2012 were 1.25 times more likely to survive 2 years than those diagnosed in 2006. MM patients showed improved survival over the study period, with the 2-year survival gap between MM patients and matched controls decreasing at a rate of 3% per year. Total costs among MM patients have increased in all healthcare services over the years; however, the relative contribution of drug costs has remained fairly stable since 2009 despite new novel therapies coming to market. Findings from this study corroborate clinical data, suggesting a paradigm shift in MM treatment over the past decade that is associated with substantial survival gains. Future studies should focus on the impact on specific novel agents on patients’ outcomes.
ISSN:0887-6924
1476-5551
DOI:10.1038/leu.2016.380